DALLAS, Feb. 7 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. announced today that Jeffrey B. Davis, Chairman and CEO of Access, is scheduled to deliver a presentation about the company at the 10th Annual BIO CEO & Investor Conference on February 13, 2008 at 12:30 pm Eastern Time. The conference will take place February 11-13, 2008 in New York City at the Waldorf Astoria Hotel.
The presentation will be webcast live via the Company’s web site at http://www.accesspharma.com.
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access’ products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate (“PB”), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access’ plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-KSB and other reports filed by Access with the Securities and Exchange Commission.
CONTACT: Stephen B. Thompson, Vice President, Chief Financial Officer of
Access Pharmaceuticals, Inc., +1-214-905-5100; or Investors, Donald C.
Weinberger, or Media, Alisa Steinberg, both of Wolfe Axelrod Weinberger
Assoc. LLC, +1-212-370-4500; or Andrew Hellman of CEOcast, Inc.,
+1-212-732-4300, all for Access Pharmaceuticals, Inc.
Web site: http://www.accesspharma.com/
